Form 4: Brainstorm Cell Therapeutics Officer Reports Acquisition of Restricted Stock

Alla Patlis, Interim CFO & Controller of Brainstorm Cell Therapeutics, reports acquiring 40,000 shares of restricted stock on January 1, 2025, under the company's 2014 Global Share Option Plan.

Summary

• On January 1, 2025, Alla Patlis, Interim CFO & Controller of Brainstorm Cell Therapeutics, reported a transaction involving the company's common stock.
• Patlis acquired 40,000 shares of restricted stock under the Issuer's 2014 Global Share Option Plan.
• These shares were acquired at a price of $0.00.
• The shares vest in two tranches: 50% on the six-month anniversary of the grant date and the remaining 50% on the eighteen-month anniversary, contingent upon continued employment.
• Following the reported transaction, Patlis beneficially owns 44,349 shares of common stock.
• The report also reflects the Issuer's 1-for-15 reverse stock split effected market open on October 1, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of restricted stock by an officer suggests confidence, but it's a routine transaction.

Positives

• The acquisition of restricted stock by a company officer can be seen as a positive sign, indicating confidence in the company's future performance.
• The vesting schedule incentivizes the officer to remain with the company for the long term.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule of the restricted stock suggests an expectation of continued employment and contribution from the reporting person.

Industry Context

Form 4 filings are standard disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company insiders and their confidence in the company's prospects.

Comparison to Industry Standards

• Form 4 filings are a standard regulatory requirement for publicly traded companies in the United States, ensuring transparency in insider trading.
• Similar filings are made by officers and directors of companies like Amgen, Biogen, and Vertex Pharmaceuticals when they engage in transactions involving their company's stock.
• The vesting schedule of the restricted stock is a common practice to align the interests of the officer with the long-term performance of the company, similar to practices observed in other biotech firms.

Stakeholder Impact

• The acquisition of restricted stock by a company officer can have a minor positive impact on shareholder sentiment, as it signals confidence in the company's future.

Key Dates

Keywords

Brainstorm Cell Therapeutics, BCLI, Alla Patlis, restricted stock, Form 4, insider trading, stock options, reverse stock split